Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection
Open Access
- 1 March 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (3) , 845-851
- https://doi.org/10.1128/aac.45.3.845-851.2001
Abstract
Daptomycin is a lipopeptide antibiotic with activity against gram-positive bacteria, including Staphylococcus aureus . We defined the pharmacodynamic parameters that determine the activity of daptomycin for S. aureus using in vitro methods and the Craig (W. A. Craig, J. Redington, and S. C. Ebert, J. Antimicrob. Chemother. 27[Suppl. C]:29–40, 1991) neutropenic mouse thigh infection model. In Mueller-Hinton broth, the MICs for three S. aureus isolates were 0.1 to 0.2 μg/ml. In mouse serum, the MICs were 1.0 μg/ml. The protein binding of daptomycin was 90 to 92.5% in mouse serum. Single-dose intraperitoneal (i.p.) pharmacokinetic studies with infected mice showed a linear relationship between dose versus the maximum concentration of drug in serum and dose versus the area under the concentration-time curve (AUC). The serum half-life of daptomycin in infected mice was approximately 1.8 h. In single-dose, dose-ranging studies using mice, daptomycin showed a dose-response effect described by an inhibitory sigmoid E max (maximum effect) curve ( r = 0.974; P ≪ 0.001). The density of S. aureus in untreated controls was 8.26 log 10 CFU/g, and the E max was 3.97 log 10 CFU/g. The 50% effective dose (ED 50 ) was 3.7 mg/kg of body weight i.p. and the stasis dose was 7.1 mg/kg. Dose fractionation studies at schedules of Q6h, Q12h, and Q24h, for total 24-h ED 30 , ED 60 , and ED 80 doses of 2.5, 5.6, and 15 mg/kg i.p., showed no difference in effect at each total 24-h dose level by schedule, indicating that the AUC/MIC ratio is the dynamically linked variable.Keywords
This publication has 31 references indexed in Scilit:
- Daptomycin: a novel agent for Gram-positive infectionsExpert Opinion on Investigational Drugs, 1999
- Staphylococcus aureusInfectionsNew England Journal of Medicine, 1998
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Bactericidal activity of vancomycin, daptomydn, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faeciumJournal of Antimicrobial Chemotherapy, 1990
- Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal ModelThe Journal of Infectious Diseases, 1988
- Role of pharmacokinetics in the outcome of infectionsAntimicrobial Agents and Chemotherapy, 1988
- Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory ConcentrationThe Journal of Infectious Diseases, 1987
- Once-Daily vs. Continuous Aminoglycoside Dosing: Efficacy and Toxicity in Animal and Clinical Studies of Gentamicin, Netilmicin, and TobramycinThe Journal of Infectious Diseases, 1983
- Constant Infusions vs. Intermittent Doses of Gentamicin Against Pseudomonas aeruginosa in VitroThe Journal of Infectious Diseases, 1982
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974